 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
|
|
|
|
Phase III
|
|
|
|
SJCRH-SJMB03
NCT00085202
|
|
| |
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
|
|
|
|
Phase III
|
|
|
|
CHLA-HEAD-START-III
CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
|
|
| |
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
|
|
|
|
Phase III
|
|
|
|
COG-ACNS0333
ACNS0333, NCT00653068
|
|
| |
A Multi-Center Phase I Study of AP23573 in Pediatric Patients With Advanced Solid Tumors
|
|
|
|
Phase II, Phase I
|
|
|
|
SUN08-01
NCT00704054
|
|
| |
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
|
|
|
Phase II, Phase I
|
|
|
|
CHNMC-07053
07053, CA180 121, NCT00788125
|
|
| |
Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System
|
|
|
|
Phase II
|
|
|
|
BC-BT-14
NCT00003469
|
|
| |
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
|
|
|
|
Phase II
|
|
|
|
MSKCC-05122
NCT00445965
|
|
| |
Gemcitabine and Oxaliplatin in Treating Young Patients With Refractory or Relapsed Solid Tumors
|
|
|
|
Phase II
|
|
|
|
CCLG-NAG-2007-01
ITCC-004-GEMOX, CCLG-IGR-1205, EU-20745, EUDRACT-2006-001065-41, NCT00407433
|
|
| |
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
|
|
|
|
Phase II
|
|
|
|
NYU 05-40 H12853
PBMTC ONC-032P, NCT00528437
|
|
| |
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
|
|
|
|
Phase I
|
|
|
|
MSKCC-03133
NCT00089245
|
|
